Spero Therapeutics, Inc.

SPRONASDAQHealthcare● Active

$2.74

$-0.08(-2.84%)

Market Cap$158650091

P/E Ratio—

52W High$3.22

52W Low$1.8

Avg Volume524K

Open$2.84

Beta1.46

Net Income Financials Revenue

Spero Therapeutics, Inc. (SPRO) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

SPRO · net income · updated Jun 9, 2026

Core profitability metrics

SPRO · net income · margin · TTM · CAGR

Net income was $8.6M for FY2025 (fiscal year ending 2025-12-31), up 112.5% year-over-year. Net profit margin was 14.4%. Based on available data, Spero Therapeutics, Inc. has been profitable since at least 2023.

FY2025 Net Income$8.6M▲ +112.5% YoY

Trailing 12M (TTM)$15.2Mtrailing 4 quarters sum

Net Profit Margin14.4%$8.6M ÷ $59.6M

YoY Change+112.5%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2023

▸ FMP /income-statement · Annual · SPRO net income history · SPRO profit margin

Annual net income data

SPRO · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025$8.6M▲ +112.5%14.4%$59.6M

FY2024Loss−$68.6M▼ 400.6%-142.9%$48.0M

FY2023★ First Profit$22.8M▲ +149.1%22.0%$103.8M

FY2022Loss−$46.4M▲ +48.3%-95.5%$48.6M

FY2021Loss−$89.8M▼ 14.7%-2923.7%$3.1M

Net income vs peers (Healthcare)

SPRO vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Spero Therapeutics, Inc.YOU

SPRO

$8.6M+112.5%14.4%

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Spero Therapeutics, Inc. (SPRO) reported net income of $8.6M for FY2025 (fiscal year ending 2025-12-31), up 112.5% year-over-year. The net profit margin was 14.4% — meaning the company kept $0.14 of every dollar of revenue as profit.

Based on available data, Spero Therapeutics, Inc. has been profitable since at least 2023. Net income reached a peak of $22.8M in FY2023. Data available for 11 fiscal years.

Spero Therapeutics, Inc.'s net profit margin was 14.4% for FY2025, based on the latest annual results.

Investors sometimes search for "Spero Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from SPRO net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

SPRO net income · 5 questions

Spero Therapeutics, Inc. is profitable. The company reported net income of $8.6M for FY2025, a net profit margin of 14.4%. Net income was up 112.5% year-over-year. Based on available data, Spero Therapeutics, Inc. has been profitable since at least 2023.

is SPRO profitabledoes SPRO make a profitSPRO profitabilitySPRO profitable company

▸ Source: FMP /income-statement · GAAP · Spero Therapeutics, Inc. · Spero Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026